These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

445 related items for PubMed ID: 23823157

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.
    Coen JJ, Zhang P, Saylor PJ, Lee CT, Wu CL, Parker W, Lautenschlaeger T, Zietman AL, Efstathiou JA, Jani AB, Kucuk O, Souhami L, Rodgers JP, Sandler HM, Shipley WU.
    J Clin Oncol; 2019 Jan 01; 37(1):44-51. PubMed ID: 30433852
    [Abstract] [Full Text] [Related]

  • 3. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.
    Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, Toonkel LM, Jones CU, Roberts JD, Shipley WU.
    Int J Radiat Oncol Biol Phys; 2003 Nov 01; 57(3):665-72. PubMed ID: 14529770
    [Abstract] [Full Text] [Related]

  • 4. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response.
    Kaufman DS, Winter KA, Shipley WU, Heney NM, Chetner MP, Souhami L, Zlotecki RA, Sause WT, True LD.
    Oncologist; 2000 Nov 01; 5(6):471-6. PubMed ID: 11110598
    [Abstract] [Full Text] [Related]

  • 5. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.
    Kaufman DS, Winter KA, Shipley WU, Heney NM, Wallace HJ, Toonkel LM, Zietman AL, Tanguay S, Sandler HM.
    Urology; 2009 Apr 01; 73(4):833-7. PubMed ID: 19100600
    [Abstract] [Full Text] [Related]

  • 6. Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.
    Mitin T, George A, Zietman AL, Heney NM, Kaufman DS, Uzzo RG, Dreicer R, Wallace HJ, Souhami L, Dobelbower MC, Sandler HM, Shipley WU.
    Int J Radiat Oncol Biol Phys; 2016 Jan 01; 94(1):67-74. PubMed ID: 26700703
    [Abstract] [Full Text] [Related]

  • 7. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer.
    Zietman AL, Shipley WU, Kaufman DS, Zehr EM, Heney NM, Althausen AF, McGovern FJ.
    J Urol; 1998 Nov 01; 160(5):1673-7. PubMed ID: 9783929
    [Abstract] [Full Text] [Related]

  • 8. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L, Bladou F, Bardou VJ, Gravis G, Tallet A, Alzieu C, Serment G, Salem N.
    Urology; 2004 Sep 01; 64(3):488-93. PubMed ID: 15351577
    [Abstract] [Full Text] [Related]

  • 9. Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer.
    Chen WC, Liaw CC, Chuang CK, Chen MF, Chen CS, Lin PY, Chang PL, Chu SH, Wu CT, Hong JH.
    Int J Radiat Oncol Biol Phys; 2003 Jul 01; 56(3):726-33. PubMed ID: 12788178
    [Abstract] [Full Text] [Related]

  • 10. Words of wisdom. Re: Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.
    van der Poel H.
    Eur Urol; 2014 Jun 01; 65(6):1221-2. PubMed ID: 24774829
    [No Abstract] [Full Text] [Related]

  • 11. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.
    Jiang DM, Jiang H, Chung PWM, Zlotta AR, Fleshner NE, Bristow RG, Berlin A, Kulkarni GS, Alimohamed NS, Lo G, Sridhar SS.
    Clin Genitourin Cancer; 2019 Feb 01; 17(1):38-45. PubMed ID: 30686350
    [Abstract] [Full Text] [Related]

  • 12. Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival.
    Lee CY, Yang KL, Ko HL, Huang RY, Tsai PP, Chen MT, Lin YC, Hwang TI, Juang GD, Chi KH.
    Radiat Oncol; 2014 Sep 24; 9():213. PubMed ID: 25248470
    [Abstract] [Full Text] [Related]

  • 13. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
    Varveris H, Delakas D, Anezinis P, Haldeopoulos D, Mazonakis M, Damilakis J, Metaxaris G, Chondros N, Mavromanolakis E, Daskalopoulos G, Dimitrakopoulos A, Kranidis A.
    Anticancer Res; 1997 Sep 24; 17(6D):4771-80. PubMed ID: 9494605
    [Abstract] [Full Text] [Related]

  • 14. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W, Choy H.
    Lancet Oncol; 2015 Feb 24; 16(2):187-99. PubMed ID: 25601342
    [Abstract] [Full Text] [Related]

  • 15. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial.
    Reynolds JV, Preston SR, O'Neill B, Lowery MA, Baeksgaard L, Crosby T, Cunningham M, Cuffe S, Griffiths GO, Parker I, Risumlund SL, Roy R, Falk S, Hanna GB, Bartlett FR, Alvarez-Iglesias A, Achiam MP, Nilsson M, Piessen G, Ravi N, O'Toole D, Johnston C, McDermott RS, Turkington RC, Wahed S, Sothi S, Ford H, Wadley MS, Power D, Neo-AEGIS Investigators and Trial Group.
    Lancet Gastroenterol Hepatol; 2023 Nov 24; 8(11):1015-1027. PubMed ID: 37734399
    [Abstract] [Full Text] [Related]

  • 16. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802.
    Tester W, Caplan R, Heaney J, Venner P, Whittington R, Byhardt R, True L, Shipley W.
    J Clin Oncol; 1996 Jan 24; 14(1):119-26. PubMed ID: 8558186
    [Abstract] [Full Text] [Related]

  • 17. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
    Lv X, Cao X, Xia WX, Liu KY, Qiang MY, Guo L, Qian CN, Cao KJ, Mo HY, Li XM, Li ZH, Han F, He YX, Liu YM, Wu SX, Bai YR, Ke LR, Qiu WZ, Liang H, Liu GY, Miao JJ, Li WZ, Lv SH, Chen X, Zhao C, Xiang YQ, Guo X.
    Lancet Oncol; 2021 May 24; 22(5):716-726. PubMed ID: 33857411
    [Abstract] [Full Text] [Related]

  • 18. Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer.
    Lin CC, Hsu CH, Cheng JC, Huang CY, Tsai YC, Hsu FM, Huang KH, Cheng AL, Pu YS.
    Int J Radiat Oncol Biol Phys; 2009 Oct 01; 75(2):442-8. PubMed ID: 19307067
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer.
    Choudhury A, Swindell R, Logue JP, Elliott PA, Livsey JE, Wise M, Symonds P, Wylie JP, Ramani V, Sangar V, Lyons J, Bottomley I, McCaul D, Clarke NW, Kiltie AE, Cowan RA.
    J Clin Oncol; 2011 Feb 20; 29(6):733-8. PubMed ID: 21205754
    [Abstract] [Full Text] [Related]

  • 20. Combination transurethral resection, systemic chemotherapy, and pelvic radiotherapy for invasive (T2-T4) bladder cancer unsuitable for cystectomy: a phase I/II Southwestern Oncology Group study.
    Einstein AB, Wolf M, Halliday KR, Miller GJ, Hafermann M, Lowe BA, Meyers FJ, Leimert JT, Crawford ED.
    Urology; 1996 May 20; 47(5):652-7. PubMed ID: 8650861
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.